Enlivex (ENLV) Change in Accured Expenses (2015 - 2025)
Enlivex (ENLV) posted quarterly Change in Accured Expenses of $1.3 million for Q4 2025, up 405.81% year-over-year from $258000.0 in Q4 2024, and up 1025.53% quarter-over-quarter from -$141000.0 in Q3 2025.
Enlivex (ENLV) Change in Accured Expenses (2015 - 2025) Analysis & Trends
Enlivex's Change in Accured Expenses history runs 11 years deep, the most recent figure standing at $1.3 million for Q4 2025.
- In Q4 2025, Change in Accured Expenses rose 405.81% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.1 million (up 202.97% YoY), while the FY2025 annual figure was $1.1 million, up 202.97% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at $1.3 million, up from -$141000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.3 million in Q4 2025, with the low at -$1.0 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is $28500.0 (2022), against an average of -$5050.0.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 485.95% in 2022, then plunged 254.27% in 2023.
- Enlivex's Change in Accured Expenses stood at $185000.0 in 2021, then soared by 485.95% to $1.1 million in 2022, then slipped by 25.09% to $812000.0 in 2023, then sank by 68.23% to $258000.0 in 2024, then jumped by 405.81% to $1.3 million in 2025.
- Business Quant data shows ENLV's Change in Accured Expenses at $1.3 million in Q4 2025, -$141000.0 in Q3 2025, and $150000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | -141,000.00 |
| Sep 30, 2025 | -141,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | -239,000.00 |
| Mar 31, 2025 | -239,000.00 |
| Dec 31, 2024 | 258,000.00 |
| Dec 31, 2024 | 258,000.00 |
| Sep 30, 2024 | 151,000.00 |
| Sep 30, 2024 | 151,000.00 |
| Jun 30, 2024 | -423,000.00 |
| Jun 30, 2024 | -423,000.00 |
| Mar 31, 2024 | -1.03 Mn |
| Mar 31, 2024 | -1.03 Mn |
| Dec 31, 2023 | 812,000.00 |
| Dec 31, 2023 | 812,000.00 |
| Sep 30, 2023 | 227,000.00 |
| Sep 30, 2023 | 227,000.00 |